Test Summary

The Epstein-Barr Virus (EBV) is the causative agent of Infectious Mononucleosis (IM). IM is an acute illness characterized clinically by sore throat, fever and lymphadenopathy. In children, 5-10% of primary EBV infections are asymptomatic. By adulthood, 90-95% of most populations have demonstrable EBV antibodies. EBV-specific serodiagnostic tests are not usually needed in typical cases of IM, since 90% of the cases are heterophile-positive. For heterophile-negative cases and for diagnosis in atypical cases, confirmation of infection by EBV-specific serology is useful. The serodiagnosis of IM is established with a single acute phase serum by the detection of elevated levels of IgM and IgG antibodies to Viral Capsid Antigen (VCA). Antibody conversion or decline in VCA-IgM antibodies (they usually disappear within 3-6 weeks after onset) and the emergence of EBNA antibodies (they arise from 3 weeks to several months after onset) can confirm diagnosis. Previous EBV infections are identified by IgG antibodies to VCA and to EBNA.

Aliases

Specimen Collection

Order Code

EPIC (Premier) Code

Includes

CPT Code

Billing Code

CPT Statement

Methodology

FDA Status

Physician Attestation of Informed Consent

Testing Laboratory

Department

Reference Range

Setup Schedule / Expected Turnaround Time